KRAS A146 Mutations Are Associated With Distinct Clinical Behavior in Patients With Colorectal Liver Metastases.
Iris van 't ErveNina J WesdorpJamie E MedinaLeonardo FerreiraAlessandro LealJoost HuiskensKaren BolhuisJan-Hein T M van WaesbergheRutger-Jan SwijnenburgDaan van den BroekVictor E VelculescuGeert KazemierCornelis J A PuntGerrit A MeijerRemond J A FijnemanPublished in: JCO precision oncology (2021)
Patients with mCRC with a KRAS A146 mutation represent a distinct molecular subgroup of patients with higher tumor burden and worse clinical outcomes, who might benefit from more intensive treatments. These results highlight the importance of testing colorectal cancer for all KRAS mutations in routine clinical care.